Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Healios KK Ord Shs > Most recent
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by 25Centson May 12, 2010 12:57pm
350 Views
Post# 17090539

RE: Most recent

RE: Most recentHello, Sweenby....

Based on my observation, you need relax..

I use TD, I bought 11808 Shares today at 0.045, time is 9:57am.. It did show 11000 with #1 and 808 with TD...
Also, TD has different trading sys : TSX and Alpha...  If you check HLO:CN at Bloomberg... right now,, It shows different price with much higher volume ... Does it help you relax ?

Just my 25 cents,,,, This is good play .... however ,,, too many individual inverstors here ... Let me guess you have more than 2 millions shares HLO.V ? That is NOT good for VENTURE stocks... Fund managers or Market traders would not allow other individual investors have too large position in it before taking off ... 

It is game..

Again,,, only my 25 cents.. 

GLTA
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities